Table 2.

Clinical performance of the BinaxNOW test and the Trinity FST for detection of deficiency in G6PD activity compared with Trinity quantitative test.

Cutoff value, U/g Hb (percent of adjusted normal male median value = 7.18)	10% Activity cutoff	20% Activity cutoff	30% Activity cutoff	60% Activity cutoff
Cutoff value, U/g Hb	0.718	1.436	2.154	4.308
No. of samples with G6PD levels below cutoff (%) [no. of M + no. of F]	6 (2.80) [6 M]	16 (7.48) [15 M + 1 F]	18 (8.41) [16 M + 2 F]	23 (10.75) [17 M + 6 F]
BinaxNOW G6PD test
Sensitivity % (95% CI)	100.0 (54.1–100.0)	100.0 (79.4–100.0)	100.0 (81.5–100.0)	82.6 (61.2–95.0)
Specificity % (95% CI)	93.3 (88.9–96.4)	98.4 (95.3–99.7)	99.5 (97.0–100.0)	100.0 (97.9–100.0)
PPV % (95% CI)	31.6 (12.6–56.6)	84.2 (60.4–96.6)	94.7 (74.0–99.9)	100.0 (82.4–100.0)
NPV % (95% CI)	100.0 (98–100.0)	100.0 (98–100.0)	100.0 (98.0–100.0)	97.8 (94.5–99.4)
Trinity fluorescent spot test*
Sensitivity % (95% CI)	100.0 (54.1–100.0)	100.0 (79.4–100.0)	100.0 (81.5–100.0)	91.3 (72.0–98.9)
Specificity % (95% CI)	90.9 (86.1–94.4)	95.5 (91.5–97.9)	96.4 (92.8–98.6)	97.9 (94.7–99.4)
PPV % (95% CI)	24.0 (9.36–45.1)	64.0 (42.5–82.0)	72.0 (50.6–87.9)	84.0 (63.9–95.5)
NPV % (95% CI)	100.0 (98.1–100.0)	100.0 (98.1–100.0)	100.0 (98.1–100.0)	98.9 (96.2–99.9)
Trinity fluorescent spot test†
Sensitivity % (95% CI)	83.3 (35.9–94.6)	75.0 (47.6–92.7)	72.2 (46.5–90.3)	56.5 (34.5–76.8)
Specificity % (95% CI)	96.2 (92.6–98.3)	99.5 (97.2–100.0)	100.0 (98.1–100.0)	100.0 (98.1–100.0)
PPV % (95% CI)	38.5 (13.9–68.4)	92.3 (64.0–99.8)	100.0 (75.3–100.0)	100.0 (75.3–100.0)
NPV % (95% CI)	99.5 (97.3–100.0)	98.0 (95.0–99.5)	97.5 (94.3–99.2)	95.0 (91.0–97.6)

CI = confidence interval; F = female; M = male.

^*Trinity fluorescent spot test: intermediate test results combined with deficient test results.

^†Trinity fluorescent spot test: intermediate test results combined with normal test results.